Bio Rad Laboratories (BIO) Stock
Life science and clinical diagnostics instruments and reagents provider. Here's the price, business snapshot, and what's worth knowing about Bio Rad Laboratories in October 2026.
Bio‑Rad Laboratories, Inc. (BIO) designs and sells instruments, reagents and software for life‑science research and clinical diagnostics. The business is organised mainly into two segments: Life Science, which serves academic and industrial researchers, and Clinical Diagnostics, which supplies hospitals and clinical laboratories. Revenue benefits from recurring consumables and service contracts alongside new equipment sales, giving a mix of predictable and cyclical income. The company invests in R&D and occasionally grows through acquisitions, with global distribution and an installed base that supports aftermarket demand. Key risks include regulatory approvals, reimbursement dynamics in diagnostics, competition, foreign‑exchange exposure and potential execution risks from integration or capital projects. Market cap is roughly $8.9bn. This summary is for educational purposes only and not personalised investment advice; investments can fall as well as rise and you should consider your own circumstances or consult a financial adviser.
Bio Rad Laboratories (BIO) Stock Forecast
Analyst price target, next 12 months
$332.50
-9.9% vs today's $369.14
Price range over the last 12 months
Close to its 12-month high
Analysts covering Bio Rad Laboratories have a consensus 12-month target of $332.50, below the current price of $369.14.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Bio-Rad's stock, indicating there is little reason to buy or sell now.
Financial Health
Bio Rad Laboratories is performing well with strong revenue, cash flow, and profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring Consumables Appeal
A significant portion of revenue comes from consumables and service contracts, which can provide steady cash flow — though demand can fluctuate with research funding and testing volumes.
Global Customer Base
Sales span academic research, biotech and clinical labs worldwide, offering diversification across markets, but international exposure brings currency and regulatory risks.
R&D and Innovation
Continued investment in R&D and selective acquisitions can drive new product cycles, yet execution and integration risk mean outcomes are not assured.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
